Table S1 Characteristics of patients with high or low NK cells

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Number (%) or Median (Range) | | *P* Value |
|  | NK cells  high (N = 10) | low (N = 9) |  |
| Age | 74.5 (52-78) | 68 (63-77) | 0.3452 |
| Gender |  |  |  |
| Male | 7 (70) | 7 (77.8) | 0.7007 |
| Female | 3 (30) | 2 (22.2) |  |
| Performance status |  |  |  |
| 0 | 8 (80) | 6 (66.7) | 0.5099 |
| 1 | 2 (20) | 3 (33.3) |  |
| Histology |  |  |  |
| Adenocarcinoma | 6 (60) | 7 (77.8) | 0.4052 |
| Squamous cell carcinoma | 4 (40) | 2 (22.2) |  |
| Disease stage |  |  |  |
| IVB | 4 (40) | 6 (66.7) | 0.4655 |
| IVA | 3 (30) | 2 (22.2) |  |
| IIIB | 2 (20) | 0 |  |
| Postoperative recurrence | 1 (10) | 1 (11.1) |  |
| PD-L1 TPS |  |  |  |
| <1% | 3 (30) | 0 | 0.1039 |
| 1-49% | 1 (10) | 3 (33.3) |  |
| ≥50% | 6 (60) | 3 (33.3) |  |
| Unknown | 0 | 3 (33.3) |  |
| Regimen of ICI/chemotherapy |  |  |  |
| CDDP+PEM+Pembro | 0 | 4 (44.4) | 0.1054 |
| CBDCA+PEM+Pembro | 5 (50) | 3 (33.3) |  |
| CBDCA+nab-PTX+Pembro | 4 (40) | 2 (22.2) |  |
| CBDCA+PTX+Atezo+BEV | 1 (10) | 0 |  |
| Leukocyte count (/μl) |  |  |  |
| Neutrophils | 4895 (2420-8090) | 5970 (4690-10410) | 0.0435 |
| Lymphocytes | 1310 (1120-2420) | 1410 (730-2570) | 0.5620 |
| Monocytes | 550 (250-1670) | 450 (280-930) | 0.6191 |

NK cell, natural killer cells; TPS, tumor proportion score; CDDP, Cisplatin; PEM, Pemetrexed; CBDCA, Carboplatin; PTX, Paclitaxel; Pembro, Pembrolizumab; Atezo, Atezolizumab; BEV, Bevacizumab

Table S2 Characteristics of patients with high or low CD4+ PD-1+ Tim-3+ cells

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Number (%) or Median (Range) | | *P* Value |
|  | CD4+ PD-1+ Tim-3+ high (N = 10) | low (N = 9) |  |
| Age | 69.5 (52-78) | 69 (63-77) | 0.9844 |
| Gender |  |  |  |
| Male | 6 (60) | 8 (88.9) | 0.1533 |
| Female | 4 (40) | 1 (11.1) |  |
| Performance status |  |  |  |
| 0 | 10 (100) | 4 (44.4) | 0.6370 |
| 1 | 3 (30) | 2 (22.2) |  |
| Histology |  |  |  |
| Adenocarcinoma | 8 (80) | 5 (55.6) | 0.2524 |
| Squamous cell carcinoma | 2 (20) | 4 (44.4) |  |
| Disease stage |  |  |  |
| IVB | 4 (40) | 6 (66.7) | 0.0611 |
| IVA | 5 (50) | 0 |  |
| IIIB | 0 | 2 (22.2) |  |
| Postoperative recurrence | 1 (10) | 1 (11.1) |  |
| PD-L1 TPS |  |  |  |
| <1% | 2 (20) | 1 (11.1) | 0.1311 |
| 1-49% | 0 | 4 (44.4) |  |
| ≥50% | 6 (60) | 3 (33.3) |  |
| Unknown | 2 (20) | 1 (11.1) |  |
| Regimen of ICI/chemotherapy |  |  |  |
| CDDP+PEM+Pembro | 2 (20) | 2 (22.2) | 0.5479 |
| CBDCA+PEM+Pembro | 5 (50) | 3 (33.3) |  |
| CBDCA+nab-PTX+Pembro | 2 (20) | 4 (44.4) |  |
| CBDCA+PTX+Atezo+BEV | 1 (10) | 0 |  |
| Leukocyte count (/μl) |  |  |  |
| Neutrophils | 4895 (2420-10410) | 5400 (4690-7750) | 0.3562 |
| Lymphocytes | 1465 (1100-2420) | 1360 (730-2570) | 0.6174 |
| Monocytes | 465 (1670-250) | 560 (380-930) | 0.4116 |

TPS, tumor proportion score; CDDP, Cisplatin; PEM, Pemetrexed; CBDCA, Carboplatin; PTX, Paclitaxel; Pembro, Pembrolizumab; Atezo, Atezolizumab; BEV, Bevacizumab

Table S3 Characteristics of patients with high or low CXCL10

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Number (%) or Median (Range) | | *P* Value |
|  | CXCL10  high (N = 10) | low (N = 9) |  |
| Age | 74.5 (63-78) | 66 (52-77) | 0.0293 |
| Gender |  |  |  |
| Male | 6 (60) | 8 (88.9) | 0.1533 |
| Female | 4 (40) | 1 (11.1) |  |
| Performance status |  |  |  |
| 0 | 9 (90) | 5 (55.6) | 0.0887 |
| 1 | 1 (10) | 4 (44.4) |  |
| Histology |  |  |  |
| Adenocarcinoma | 5 (50) | 8 (88.9) | 0.0686 |
| Squamous cell carcinoma | 5 (50) | 1 (11.1) |  |
| Disease stage |  |  |  |
| IVB | 4 (40) | 6 (66.7) | 0.4655 |
| IVA | 3 (30) | 2 (22.2) |  |
| IIIB | 2 (20) | 0 |  |
| Postoperative recurrence | 1 (10) | 1 (11.1) |  |
| PD-L1 TPS |  |  |  |
| <1% | 1 (10) | 2 (22.2) | 0.6552 |
| 1-49% | 2 (20) | 2 (22.2) |  |
| ≥50% | 6 (60) | 3 (33.3) |  |
| Unknown | 1 (10) | 2 (22.2) |  |
| Regimen of ICI/chemotherapy |  |  |  |
| CDDP+PEM+Pembro | 1 (10) | 3 (33.3) | 0.2013 |
| CBDCA+PEM+Pembro | 4 (40) | 4 (44.4) |  |
| CBDCA+nab-PTX+Pembro | 5 (50) | 1 (11.1) |  |
| CBDCA+PTX+Atezo+BEV | 0 | 1 (11.1) |  |
| Leukocyte count (/μl) |  |  |  |
| Neutrophils | 5135 (2420-10410) | 5570 (4320-8090) | 0.4002 |
| Lymphocytes | 1385 (1120-2420) | 1380 (730-2570) | 0.5897 |
| Monocytes | 500 (250-1670) | 460 (440-920) | 0.7619 |

CXCL10, chemokine C-X-C ligand 10; TPS, tumor proportion score; CDDP, Cisplatin; PEM, Pemetrexed; CBDCA, Carboplatin; PTX, Paclitaxel; Pembro, Pembrolizumab; Atezo, Atezolizumab; BEV, Bevacizumab



Supplementary Fig. 1



Supplementary Fig. 2

 Supplementary Fig. 3

 Supplementary Fig. 4

 Supplementary Fig. 5